Advanced glycation end products contribute to amyloidosis in Alzheimer disease.
Michael Peter Vitek, K Bhattacharya, J. Michael Glendening et al. · Proceedings of the National Academy of Sciences · 1994
Alzheimer disease (AD) is characterized by deposits of an aggregated 42-amino-acid beta-amyloid peptide (beta AP) in the brain and cerebrovasculature. After a concentration-dependent lag period during in vitro incubations, soluble preparations of synthetic beta AP slowly form fibrillar aggregates that resemble natural amyloid and are measurable by sedimentation and thioflavin T-based fluorescence. Aggregation of soluble beta AP in these in vitro assays is enhanced by addition of small amounts of pre-aggregated beta-amyloid "seed" material. We also have prepared these seeds by using a naturally occurring reaction between glucose and protein amino groups resulting in the formation of advanced "glycosylation" end products (AGEs) which chemically crosslink proteins. AGE-modified beta AP-nucleation seeds further accelerated aggregation of soluble beta AP compared to non-modified "seed" material. Over time, nonenzymatic advanced glycation also results in the gradual accumulation of a set of posttranslational covalent adducts on long-lived proteins in vivo. In a standardized competitive ELISA, plaque fractions of AD brains were found to contain about 3-fold more AGE adducts per mg of protein than preparations from healthy, age-matched controls. These results suggest that the in vivo half-life of beta-amyloid is prolonged in AD, resulting in greater accumulation of AGE modifications which in turn may act to promote accumulation of additional amyloid.
Cited by 804 works. doi:10.1073/pnas.91.11.4766
Authors
- Michael Peter Vitek
- J. Michael Glendening
- Edward G. Stopa
- Helen Vlassara
- Richard Bucala
- K Manogue
- Anthony Cerami
References
- Fluorometric assay of proteins in the nanogram range
- Alzheimer's disease and Down's syndrome: Sharing of a unique cerebrovascular amyloid fibril protein
- Characterization and Chromosomal Localization of a cDNA Encoding Brain Amyloid of Alzheimer's Disease
- Mutation of the β-amyloid precursor protein in familial Alzheimer's disease increases β-protein production
- Production of the Alzheimer Amyloid β Protein by Normal Proteolytic Processing
- Seeding “one-dimensional crystallization” of amyloid: A pathogenic mechanism in Alzheimer's disease and scrapie?
- A pathogenic mutation for probable Alzheimer's disease in the APP gene at the N–terminus of β–amyloid
- The carboxy terminus of the .beta. amyloid protein is critical for the seeding of amyloid formation: Implications for the pathogenesis of Alzheimer's disease
- Release of Excess Amyloid β Protein from a Mutant Amyloid β Protein Precursor
- Assembly and aggregation properties of synthetic Alzheimer's A4/beta amyloid peptide analogs.